Abstract Vascular smooth muscle cell (VSMC) growth is a primary component of accelerated and spontaneous atherosclerosis. Previous studies have shown that iron may be involved in the control of enzymatic activities that modulate DNA synthesis in human cells. In this study the effects of the iron chelator desferrioxamine on in vitro and in vivo VSMC proliferation were tested. Rat VSMCs in culture and a rabbit model of carotid artery balloon injury were used. Desferrioxamine showed a significant inhibitory effect on [ 3 H]thymidine incorporation in cell cultures that was antagonized by iron supplementation. Desferrioxamine also provided effective preventive myointimal VSMC proliferation as assessed bybromodeoxyuridine labeling and morphometric analysis of endoluminal stenosis. These experiments suggested that iron may be involved in the control of VSMC proliferation and that desferrioxamine may have a role in preventing VSMC growth and myointimal proliferative lesions. (Arterioscler Thromb. 1994;14:299-304.) Key Words • vascular smooth muscle cell proliferation • intimal thickening • iron • desferrioxamine • atherogenesis V ascular smooth muscle cell (VSMC) proliferation has been widely accepted as a primary component in the pathophysiology of spontaneous 1 and accelerated 2 atherosclerosis. Experimental studies in various animal models have shown that endothelial and arterial wall injury promotes a sequence of events characterized by proliferation and migration of smooth muscle cells in the intima that eventually leads to luminal stenosis. 3 The factors involved in this proliferative response have not yet been denned, although a number of mitogens have been implicated.
V ascular smooth muscle cell (VSMC) proliferation has been widely accepted as a primary component in the pathophysiology of spontaneous 1 and accelerated 2 atherosclerosis. Experimental studies in various animal models have shown that endothelial and arterial wall injury promotes a sequence of events characterized by proliferation and migration of smooth muscle cells in the intima that eventually leads to luminal stenosis. 3 The factors involved in this proliferative response have not yet been denned, although a number of mitogens have been implicated. 1 There is increasing evidence that iron metabolism is causally involved in normal and malignant cell proliferation. 4 Iron-dependent activity has been detected in ribonucleotide reductase 5 , a key enzyme in DNA synthesis, and inhibitory properties of cell growth have been ascribed to the iron chelator desferrioxamine (DFO). 6 -7 Furthermore, active oxygen species, the production of which is strongly catalyzed by transition metals, 8 may act as VSMC growth factors by increasing DNA synthesis and proto-oncogene expression. 9 In this context, it is worth noting that oxygen free radicals are actively produced by vascular cells 10 - 12 and even more by inflammatory cells, concomitant with the iron mobilization related to the inflammatory response. 3 ' 1319 Finally, ceruloplasmin modulates the endothelial production of platelet-derived growth factor, a potent mitogen for VSMCs, 20 - 21 possibly by controlling a ferrous iron-mediated peroxidation. Therefore, it is conceivable that manipulations of cellular iron metabolism could effectively control VSMC proliferation. On the other hand, DFO is in current clinical use for the treatment of transfusional iron overload, 22 which influences DNA synthesis in human cells 23 - 24 and represents an experimental tool with which to investigate the iron-catalyzed Haber-Weiss reaction. 8 The aim of this study was to assess the effects of DFO on VSMC proliferation and myointimal thickening in in vitro vascular smooth muscle cell cultures and in a rabbit model of arterial wall balloon injury.
Methods

Cell Cultures
VSMCs were harvested from enzymatically dissociated rat aortas and cultured as described. 25 VSMCs were characterized by using a monoclonal antibody to a-smooth muscle actin, which selectively recognizes the a-actin isoforms of smooth muscle cells, and by the "hill and valley" appearance by phase-contrast microscopy. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10% fetal calf serum (FCS) in a humidified atmosphere of 5% CO 2 /95% air at 37°C. Twice weekly the cells were subcultured at a 1:3 ratio by detachment with 0.25% trypsin and 0.02% EDTA. Culture medium was changed every 3 days. Cells were used for the assays from passages 5 through 8. 0 of the proliferative assay. After a 24-hour incubation, cells were detached with trypsin and EDTA and subsequently counted under a phase-contrast microscope with the aid of a hemocytometer. To perform the time-course experiments, DFO was added to the cultures at different times during the 24-hour incubation period. At the end of the incubation time, VSMCs were washed three times with phosphate-buffered saline (PBS), and DNA was recovered on fiberglass filter paper by using an automated cell harvester (Cambridge Technology Inc). Filter discs were placed in borosilicate glass vials, each containing 4 mL liquid scintillation fluid. The radioactivity of the filter disc was determined by using a liquid scintillation spectrometer (Packard Instrument).
DNA Synthesis
Animal Model
A predominantly fibromuscular plaque was produced by endothelial denudation in the right common carotid artery of male New Zealand White rabbits by a balloon catheter. 26 Each animal was preanesthetized with an IV infusion of diazepam 0.2 mg/kg, and anesthesia was maintained with halothane via an endotracheal tube. A 2F Fogarty embolectomy catheter was inserted into the right common carotid artery via a branch of the external carotid artery and was then inflated with air to a level that visibly distended the artery so that the balloon met with resistance during its passage through the artery. The inflated catheter was then withdrawn almost to the point of entry. This procedure was repeated for a total of three times. After removal of the balloon catheter, the branch of the external carotid artery was ligated and the skin wound sutured using 3.0 silk. The left carotid artery remained undamaged and served as an intraindividual control. The validity of the procedure for endothelial cell denudation was assessed by scanning electron microscopy of carotid arteries from animals killed immediately postoperatively (data not shown). The experimental protocol was reviewed and approved by the University of Chieti Animal Care Committee.
Study Protocol
After balloon injury, the rabbits were randomized into a pharmacologically nontreated control group and a DFOtreated group. Since VSMC intimal proliferative activity peaks during the first 7 days after vascular injury, 27 -2 * we first evaluated the influence of DFO treatment (20 mg/kg twice daily for 7 days) after balloon injury on in vivo VSMC growth. Control and treated animals were examined serially 2, 4, 7, and 28 days after injury (6 animals for each group). Subsequently, after preliminary experiments were performed to evaluate the optimum time for determination of intimal thickening, we chose a period of 3 weeks and tested at this time the effect of 1 week of treatment with DFO on intimal proliferative response (6 DFO-treated versus 6 nontreated animals).
In Vivo Bromodeoxyuridine Incorporation
Bromodeoxyuridine (BrdU) (Sigma Chemical Co), a thymidine analogue, is incorporated into the DNA of S-phase proliferating cells. 2729 To determine the extent of VSMCs undergoing DNA synthesis, BrdU 20 mg/kg dissolved in PBS was injected intraperitoneally twice daily for 48 hours before excision of the vessels. The small intestine and liver were excised to analyze the extent of BrdU taken up by the nuclei of nonvascular cells. Before excision the arteries were perfused in situ with 500 mL 0.1 mol/L cacodylate-buffered 2% paraformaldehyde solution (Sigma Chemical Co) at 180 mm Hg via a catheter inserted into the aorta. The excised vessels were embedded in paraffin and prepared for histological and immunohistological examination. A cell proliferation kit (Ylem) using a monoclonal antibody against BrdU and sequential application of biotinylated antibodies to mouse immunoglobulins followed by a complex of streptavidin and biotinylated peroxidase (Dako StreptABC Complex/HRP Duet) were used to detect all proliferating cells. 30 In addition, immunohistochemical detection of desmin (monoclonal) was performed to identify the neointimal proliferated cells as VSMCs. Proliferating VSMCs were quantified by counting all BrdU-positive cells of the intimal and medial cross-sectional areas in the region of balloon injury and in the area of the maximal desmin positivity for VSMCs. Proliferating VSMCs were quantified by total number of cells with labeled nuclei divided by the area in which they were identified. 28 
Morphometry
Animals were anesthetized 3 weeks after balloon injury, and carotid arteries were fixed by perfusion at 120 mm Hg with 1% paraformaldehyde in 0.1 mol/L cacodylate buffer, pH 7.4, via a cannula placed retrograde in the abdominal aorta. One hour before fixation, the animals were infused intravenously with Evans blue dye (Sigma Chemical Co) in PBS (60 mg/kg) to delineate the areas of endothelial damage. The arteries were further fixed overnight by immersion in Karnovsky's fixative. After fixation, specimens were extensively washed by flushing the lumen with buffer solution using a 26-gauge needle on a syringe. Three samples from the central blue region in the left carotid artery and three samples from the corresponding region in the right carotid artery were processed. Postfixation in 1% OsO 4 (Sigma Chemical Co) in 0.1 mol/L cacodylate buffer for 1 hour at 4°C was performed. After being washed in cacodylate buffer and dehydrated in alcohol, the samples were processed in Spurr low-viscosity embedding medium for crosssectioning (Polysciences, Inc). The areas of intimal and medial layers were calculated with a digital planimeter (9874A digitizer, Hewlett Packard). 
Statistical Analysis
All data are reported as mean±SD. Each experimental group was compared with a concomitant control group. The significance of differences between control and DFO-treated groups was evaluated by using a two-tailed Student's t test. Differences were considered significant at P<.05.
Results
Effect of DFO on Cell Count and [
H]Thymidine Incorporation
After a 24-hour incubation a maximal inhibition (60±7.6%) in cell count was seen using DFO at 250 junol/L (25.7xlO 3 (Fig 3) .
Serial Studies and In Vivo Quantification of VSMC Proliferation With and Without DFO Treatment
Quantification of smooth muscle cell proliferation by BrdU labeling in the neointima of the carotid artery was first identified 2 days after vascular injury. Proliferative activity peaked on day 7, with a progressive decline at 14 and 21 days (data not shown), and approached baseline values at 28 days (Fig 4) . The balloon-injured arteries of nontreated animals showed a significant increase of labeled cells at 2, 4, and 7 days with respect to noninjured arteries (left artery; data not shown). Intimal proliferation in the DFO groups was significantly reduced at 2, 4, and 7 days (Fig 5) , but no significant difference was observed at the end of the time course (Fig 4) . The differences were significant when compared with control groups (P<.001 at each treatment).
Effect of DFO on Thickening of Intimal Layers
The calculated medians of the areas of the intimal layers in the control group and in the DFO-treated animals were 0.39±0.09 and 0.25+0.05 mm 2 , respectively (P<.001). Thus, compared with nontreated controls, myointimal thickening was reduced by 36% in DFO-treated animals. The calculated medians of the areas of the medial layers in the same groups were 0.46±0.05 and 0.43±0.07 mm 2 , respectively, which were not significantly different (Fig 6) . Intimal morphology observed after balloon injury was mainly composed of VSMCs; in addition, monocytes, lymphocytes, or granulocytes were observed. 
Discussion
The present study showed that DFO causes dose-and time-dependent inhibition of VSMC proliferation in cultured cells. Furthermore, inhibitory effects are also detectable in the rabbit carotid artery subjected to endothelial denudation by balloon injury, since the intimal thickening can be prevented by a 1-week DFO administration. The in vitro inhibition of [ 3 H]thymidine incorporation, which can be prevented by simultaneous addition of equimolar concentrations of FeCl 3 , apparently emphasized the role of ferric ion chelation in modulating smooth muscle cell growth.
It is well known that iron is required for the growth of all cells, and the capacity of DFO to inhibit DNA synthesis has been demonstrated in several mammalian cells. 4 Ribonucleotide reductase, a rate-controlling enzyme in DNA synthesis, 31 is one possible target for the action of the drug. Indeed, ribonucleotide reductase, which catalyzes the enzymatic formation of deoxyribonucleotides, contains a free tyrosyl radical as part of its polypeptide structure that requires the continual presence of oxygen and iron during regeneration. 32 Therefore, the iron chelation by DFO, which results in less tyrosyl free-radical formation, 33 could be involved in the inhibition of ribonucleotide reductase activity in our VSMCs. In this context, it is interesting to note that innt\* WAIUV, tin n u n ii£cinit piuuuvCu uy Liii^ vdatuiai cells even after balloon injury, 34 -35 could inhibit VSMC proliferation, 36 possibly by tyrosyl radical inactivation. 37 Prevention of free-radical generation is another possible mechanism by which DFO may control VSMC proliferation. Oxygen free radicals may stimulate proliferation, DNA synthesis, and proto-oncogene expression in VSMCs. 9 However, even though H 2 O 2 specifically seems to increase [ 3 H]thymidine incorporation in VSMCs, a role for the hydroxyl radical, which is produced by the iron-dependent Haber-Weiss reaction, 38 in modulating H 2 O 2 -induced DNA synthesis cannot be excluded. On the other hand, cultured arterial smooth muscle cells may produce oxygen free radicals, and unlike the superoxide burst produced by activated leukocytes, superoxide production in arterial smooth muscle cells is continuous and possibly cumulative.
1012 In addition, it should be kept in mind that the oxidative capacity of these cells is greatly increased by micromolar concentrations of transition metals (eg, iron or copper). 1012 Furthermore, in an in vivo model of vascular injury we cannot exclude a possible role for endothelial and inflammatory cells in the control of oxygen species production.
1419 - 39 In fact, there is increasing evidence for the involvement of inflammatory cells and their products in VSMC proliferation and vascular occlusion after acute vascular injury 3 or during atherogenesis. 13 In this context, DFO may also act as an anti-inflammatory agent by preventing iron mobilization from ferritin in vascular cells caused by the superoxide burst of activated leukocytes. 19 - 40 Abnormalities of oxygen distribution in the arterial wall due to increased wall thickness or balloon injury may represent another source of oxyradical production. 41 Finally, DFO may block LDL oxidation, 1012 which is promoted by stimulated neutrophils in the presence of ferritin, due to superoxide-induced ferritin iron release. 42 An active role for iron chelation could be hypothesized in relation to the induction of platelet-derived growth factor gene expression by oxidized LDL in human smooth muscle cells. 43 Whether iron chelators modulate the production of vascular growth factors is a topic that remains to be determined. 20 In conclusion, the present study provided evidence that iron chelation by DFO may control in vitro and in vivo VSMC proliferation, thus suggesting a new pharmacological tool for the treatment of vascular stenosis after injury. This new documented vascular effect of DFO is in keeping with a possible role for ribonucleotide reductase activity and/or for oxygenderived free-radical damage in modulating VSMC proliferation and may emphasize a link between iron and stenosis after vascular injury. 44 
